Net World

Google completes controversial takeover of DeepMind health ...

Google has achieved a controversial take-over of the fitness division of its UK AI acquisition, DeepMind.

The personnel circulation had been delayed as country wide health carrier (NHS) trusts regarded whether to shift their existing DeepMind contracts — some for a clinical project management app, others involving predictive health AI research — to Google.

In a blog publish the day before today Dr Dominic King, previously of DeepMind (and the NHS), now UK web site lead at Google fitness, confirmed the switch, writing: "It's clear that a transition like this takes time. health data is sensitive, and we gave appropriate time and care to make certain that we had the complete consent and cooperation of our partners. This included giving them the time to ask questions and absolutely consider our plans and to choose even if to continue our partnerships. As has at all times been the case, our companions are in full control of all patient information and we can only use affected person data to support enrich care, below their oversight and instructions."

The Royal Free NHS trust, Taunton & Somerset NHS groundwork have confidence, Imperial school Healthcare NHS have confidence, Moorfields Eye health center NHS foundation have faith and tuition faculty London Hospitals NHS foundation trust all put out statements the day prior to this confirming they have got moved their contractual arrangements to Google.

within the case of the Royal Free, sufferers' Streams information is moving to the Google Cloud Platform infrastructure to guide expanding use of the app which surfaces indicators for a kidney condition to one more of its hospitals (Barnet clinic).

One NHS have confidence, Yeovil District medical institution NHS groundwork believe, has not signed a brand new contract — and says it had never deployed Streams, suggesting it had now not found a satisfactory method to combine the app with its latest ways of working — as a substitute taking the decision to terminate the arrangement. even though it's leaving the door open to future health carrier provision from Google.

A spokeswoman for Yeovil health center sent us this commentary:

We started our relationship with DeepMind in 2017 and considering then had been opting for what half the Streams application might play in medical determination making right here at Yeovil medical institution.

The app changed into under no circumstances operationalised, and no affected person information was processed.

What's key for us as a health center, when it involves since the implementation of any new piece of expertise, is whether or not it improves the effectiveness and protection of patient care and the way it tessellates with existing approaches of working. Working with the DeepMind crew, we found that Streams is not quintessential for our enterprise at the current time.

at the same time as our contractual relationship has ended, we are able to stay an anchor associate of Google fitness so will continue to be a part of conversations about rising expertise which may well be of improvement to our sufferers and our clinician sooner or later.

The hand-off of DeepMind fitness to Google, which turned into introduced simply over a yr in the past, ability the tech massive is now directly featuring software capabilities to a couple of NHS trusts that had signed contracts with DeepMind for Streams; as well as taking on a couple of AI research partnerships that contain using NHS sufferers' statistics to are trying to develop predictive diagnostic fashions using AI expertise.

DeepMind — which kicked off its health efforts with the aid of signing an agreement with the Royal Free NHS trust in 2015, happening to publicly announce the health division in spring 2016 — talked about closing year its future center of attention can be as a "analysis organisation".

As these days as this July DeepMind turned into also touting a predictive healthcare research "step forward" — saying it had informed a deep studying mannequin for normally predicting the long run probability of a patient constructing a existence-threatening condition called acute kidney injury. (notwithstanding the AI is informed on closely gender-skewed records from the U.S. branch of Veteran Affairs.)

Yet it's now develop into clear that it's passed off several of its key NHS analysis partnerships to Google health as part of the Streams transfer.

In its statement concerning the circulate the previous day, UCLH writes that "it turned into proposed" that its DeepMind analysis partnership — which is regarding radiotherapy treatment for sufferers with head and neck cancer — be transferred to Google health, asserting this will allow it to "make use of Google's scale and adventure to carry skills breakthroughs to patients extra impulsively".

"we are able to preserve control over the anonymised information and remain chargeable for determining the way it is used," it adds. "The anonymised records is encrypted and only obtainable to a constrained number of researchers who're working on this venture with UCLH's permission. entry to the statistics will only be granted for officially approved analysis functions and will be instantly audited and logged."

It's price mentioning that the concept of "anonymised" excessive dimension health records should be handled with a healthy degree of scepticism — given the risk of re-identification.

Moorfields additionally identifies Google's "substances" because the incentive for agreeing for its eye-scan connected research partnership to be surpassed off, writing: "This up to date partnership will allow us to draw on Google's resources and expertise to extend the advantages of innovations that AI presents to more of our clinicians and patients."

rather the place this leaves DeepMind's ambitions to "prepared the ground in primary research making use of AI to critical science and scientific analysis questions, in collaboration with tutorial companions, to speed up scientific growth for the advantage of everyone", as it put it final 12 months — when it characterised the hand-off to Google fitness as all about 'scaling Streams' — is still to be considered.

We've reached out to DeepMind for touch upon that. update: The enterprise told us it is now in simple terms focused on fundamental science analysis areas, which contains clinical questions, rather than utilized healthcare — citing its research into protein folding as an instance. Whereas it referred to Moorfields and UCLH have an interest within the translation of research into relevant applied sciences past primary research, making Google fitness a more robust fit.

Co-founder Mustafa Suleyman, who's been taking a go away of absence from the business, tweeted the day before today to congratulate the Google fitness team.

DeepMind's NHS analysis contracts additionally transferring to Google health suggests the tech giants desires zero separation between core AI health research and the potential of application, the usage of its own cloud infrastructure, of any promising models it's capable of coach off of patient records and commercialize with the aid of promoting to the same healthcare functions providers as apps and capabilities.

You may say Google is searching for to bundle entry to the excessive resolution patient information that's primary for establishing fitness AIs with the provision of industrial digital healthcare capabilities it hopes to promote hospitals down the road, all funnelled in the course of the identical Google cloud infrastructure.

As we mentioned on the time, the hand-off of DeepMind health to Google is controversial.

at first since the have faith that partnered with DeepMind in 2015 to boost Streams was later found through the uk's facts protection watchdog to have breached UK legislation. The ICO said there changed into no criminal foundation for the Royal Free to have shared the scientific facts of ~1.6M patients with DeepMind throughout the app's construction.

regardless of considerations being raised over the prison basis for sharing sufferers' statistics all the way through 2016 and 2017 DeepMind persevered inking NHS contracts for Streams — claiming at the time that patient facts would on no account be surpassed to Google. Yet quick ahead a few years and it's now actually sitting on the tech gigantic's servers.

It's that U-turn that led the DeepMind to Google fitness hand-off to be branded a believe demolition through criminal consultants when the news was introduced final 12 months.

This summer time the united kingdom's affected person facts watchdog, the national facts Guardian, released correspondence between her workplace and the ICO which informed the latter's 2017 finding that Streams had breached information insurance plan law — during which she articulates a clear regulatory place that the "low cost expectations" of patients have to govern non-direct care uses for people's health facts, rather than healthcare suppliers counting on doctors to come to a decision whether or not they feel the supposed intention for individuals's scientific tips is justified.

The Google fitness blog post talks a whole lot about "patient care" and "affected person information" however has nothing to say about sufferers' expectations of how their personal suggestions should be used, with King writing that "our partners are in full handle of all affected person data and we can only use affected person records to support enhance care, below their oversight and instructions".

It became precisely such an ethical blindspot around the affected person's viewpoint that led Royal Free doctors to override concerns about americans's scientific privacy in the rush to throw their lot in with Google-DeepMind and scramble for AI-fuelled predictive healthcare.

affected person consent become now not hunted for passing scientific facts then; nor have patients' views been consulted within the transfer of Streams contracts (and americans's records) to Google now.

And while — after it become confronted with public outcry over the NHS statistics it became processing — DeepMind did go on to submit its contracts with NHS trusts (with some redactions), Google health isn't providing the sort of transparency on the alternative contracts that have been inked now. So it's no longer clear no matter if there had been some other adjustments to the terms. sufferers need to take all that on have confidence.

We reached out to the Royal Free have confidence with questions in regards to the new contract with Google however a spokeswoman simply pointed us to the commentary on its web page — where it writes: "All migration and implementation can be achieved to the optimum standards of protection and will be compliant with critical facts protection law and NHS assistance governance requirements."

"as with any of our preparations with third events, the Royal Free London continues to be the statistics controller relating to all very own data. This capability we continue control over that very own data normally and are responsible for finding out how that records is used for the advantage of patient care," it provides.

In one more discount in transparency accompanying this hand-off from DeepMind to Google health, an impartial panel of reviewers that DeepMind appointed to oversee its work with the NHS in an extra bid to raise believe has been disbanded.

"As we introduced in November, that review constitution — which labored for a UK entity primarily concentrated on discovering and constructing healthcare solutions with and for the NHS — isn't the correct structure for a global effort set to work throughout continents in addition to distinct health capabilities," King proven the previous day.

In its annual record last yr the panel had warned of the risk of DeepMind exerting "extreme monopoly vigour" as a result of the information entry and streaming infrastructure bundled with provision of the Streams app. For DeepMind then study Google now.

impartial consultants elevating considerations about monopoly energy unsurprisingly doesn't align with Google's global ambitions in future healthcare provision.

The last be aware from the impartial reviewers is a Medium post penned through former chair, professor Donal O'Donoghue — who writes that he's "disappointed that the IR experiment did not have the time to run its course and that i am unhappy to claim goodbye to a assignment I've found fascinating".

"This become a desirable exploration into how a brand new governance model can be utilized to such a crucial enviornment akin to health," he adds. "It's hard to understand how this might have developed through the years but… what is obvious to me is that have faith and transparency are of paramount importance in healthcare and i'm eager to peer how Google health, and other suppliers, deliver this in the future."

but with trust demolished and transparency decreased Google health appears to have learnt exactly nothing from DeepMind's missteps.

UCLA oncologist Dennis Slamon wins 2019 Lasker Award for ...

health practitioner-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology on the David Geffen college of drugs at UCLA, has been awarded the 2019 Lasker-DeBakey medical clinical analysis Award for the groundbreaking building of breast melanoma drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-superb breast melanoma. He shares the award with H. Michael Shepard, an American melanoma researcher honored for work he accomplished at biotechnology business Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.

The Albert and Mary Lasker foundation honored Slamon and colleagues for demonstrating that monoclonal antibodies — proteins that bind to specific invader organisms or abnormal (e.g., cancerous) cells — were a plausible and helpful approach to treat strong tumors, opening a brand new course to advance and deploy antibodies to deal with cancer.

"Dennis is a scientific pioneer whose analysis has benefited countless patients and families," stated Dr. Kelsey Martin, dean of the Geffen school of drugs. "each person at UCLA is extraordinarily proud that his accomplishments are being recognized with the aid of the Lasker committee."

The building of Herceptin marked a brand new era of extra positive treatments designed to fight cancer at its genetic roots. in the early Nineteen Eighties, Slamon first identified a brand new, greater aggressive subtype of breast melanoma called HER2-superb, or HER2+. a few years later, he and his crew found out a hyperlink between the HER2+ gene mutation and aggressive breast melanoma. He then proved the conception that if researchers could establish what became broken in a cancer cellphone in comparison to a traditional phone, they may attempt to target and deal with it specifically without harmful general tissue — whatever thing many melanoma researchers doubted would be advantageous.

"there have been loads of preconceived notions that this strategy couldn't work as a result of prior antibody healing procedures in cancer had failed," stated Slamon, who's additionally the director of clinical and translational analysis at the UCLA Jonsson complete cancer center. "although, we had clear data to again us up and we definitely stuck to pursuing it. I grew up being advised that i was most effective confined via my very own skill. That all the time stayed with me. You need to be very cautious and significant of your statistics, but when it appears relevant, agree with it and chase it regardless of what others may additionally suppose."

the first human medical trial led with the aid of Slamon turned into carried out at UCLA in 1990. Twenty girls — who he credits as being the true heroes within the Herceptin construction story — participated.

"these girls who entered the section one trials aren't analysis subjects or sufferers, they're colleagues," Slamon observed. "They're each bit as a whole lot of the story as any of us because they participated in a trial understanding that we might be giving them whatever thing that would harm them. and since it changed into a security test, we needed to start at tiers that were not prone to even assist them. but they all agreed and volunteered with the angle that whereas it will possibly not at once assist them, it might help the subsequent adult in the back of them."

within the early Nineties, ladies with the HER2+ subtype had an ordinary existence expectancy after diagnosis of three to five years. these days, depending on the stage of diagnosis, women with the HER2+ subtype general seven to 10 years of sickness-free survival. An estimated 2.7 million to 3 million women everywhere were handled with the drug.

"Dr. Slamon's discoveries have revolutionized melanoma care," talked about Dr. Michael Teitell, director of the Jonsson melanoma core. "i will be able to't overstate how colossal his scientific achievements are to the container of oncology. i love him for his tenacity, force and devotion to locate extra advantageous methods to deal with americans with cancer."

Slamon and colleagues opened a wholly new enviornment of analysis. In turn, centered treatment options for cancer, including Erbitux, Sprycel, Nerlynx and Avastin, have emerged, due to research by using different scientists. Slamon continues to steer the development of groundbreaking new cures, reminiscent of palbociclib (Ibrance), which was accepted through the FDA in February 2015 for girls with superior estrogen receptor-tremendous, HER-2-bad breast melanoma.

"Over the route of his forty-yr tenure at UCLA, Dr. Slamon has persevered in his research, resulting in greater effects for patients," observed Johnese Spisso, president of UCLA health and CEO of the UCLA sanatorium equipment. "His efforts resulted in a new way of knowing breast melanoma and we are grateful for the massive have an effect on his work has had on the lives of hundreds of thousands of girls international."

A 1975 honors graduate of the school of Chicago's Pritzker college of medication, Slamon earned his doctorate in phone biology that identical 12 months. He completed his internship and residency on the school of Chicago Hospitals and Clinics, fitting chief resident in 1978. 365 days later, he grew to become a fellow within the division of hematology/oncology at UCLA.

Slamon also serves as director of the Revlon/UCLA women's cancer analysis application and is the govt vice chair for analysis at the Geffen college of medication. He has obtained dozens of country wide and foreign awards, together with the 2019 Sjöberg Prize from the Royal Swedish Academy of Sciences and Sweden's Sjöberg basis; the Medal of Honor for medical research, the American melanoma Society's highest honor; the Gairdner groundwork overseas Award; the Salk Award for Translational research; and the countrywide Library of medicine amazing scientific service Award.

the honour marks the 2nd year in a row that a UCLA scientist has received the Lasker Award, one in every of the united states's most prestigious biomedical analysis awards. Michael Grunstein, a uncommon professor of organic chemistry on the Geffen college of medicine, become awarded the 2018 Albert Lasker basic clinical analysis Award for his groundbreaking research on gene expression.

The Lasker Awards, broadly viewed as the us's appropriate biomedical analysis prize, can be presented Sept. 20 in ny by using the Lasker basis. the honour incorporates a prize of $250,000, which Slamon, Shepard and Ullrich will cut up equally. The basis recognizes essentially the most vital achievements in science and public carrier, helps and encourages the scientific leaders of day after today, and raises attention of the want for research funding. dependent in 1942 by means of Albert and Mary Lasker, the basis is dedicated to inspiring support for biomedical research.

Watch a Lasker foundation video about Slamon and the story of Herceptin.